Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir : A Phase 2 Open-label Randomized Controlled Trial
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Early antiviral therapy was effective in the treatment of coronavirus disease 2019 (COVID-19). We assessed the efficacy and safety of combined interferon beta-1b and remdesivir treatment in hospitalized COVID-19 patients.
METHODS: We conducted a multicentre, prospective open-label, randomized-controlled trial involving high-risk adults hospitalized for COVID-19. Patients were randomly assigned to a 5-day interferon beta-1b 16 million units daily and remdesivir 200 mg loading on day 1 followed by 100 mg daily on day 2 to 5 (combination group), or to remdesivir only of similar regimen (control group) (1:1). The primary endpoint was the time to complete alleviation of symptoms (NEWS2 = 0).
RESULTS: Two-hundred and twelve patients were enrolled. The median days of starting treatment from symptom onset was 3 days. The median age was 65 years, and 159 patients (75%) had chronic disease. The baseline demographics were similar. There was no mortality. For the primary endpoint, the combination group was significantly quicker to NEWS2 = 0 (4 vs 6.5 days; hazard ratio [HR], 6.59; 95% confidence interval [CI], 6.1-7.09; P < .0001) when compared to the control group. For the secondary endpoints, the combination group was quicker to negative nasopharyngeal swab (NPS) viral load (VL) (6 vs 8 days; HR, 8.16; 95% CI, 7.79-8.52; P < .0001) and to develop seropositive immunoglobulin G (IgG) (8 vs 10 days; HR, 10.78; 95% CI, 9.98-11.58; P < .0001). All adverse events resolved upon follow-up. Combination group (HR, 4.1 95% CI, 1.9-8.6, P < .0001) was the most significant independent factor associated with NEWS2 = 0 on day 4.
CONCLUSIONS: Early treatment with interferon beta-1b and remdesivir was safe and better than remdesivir only in alleviating symptoms, and in shortening viral shedding and hospitalization with earlier seropositivity in high-risk COVID-19 patients.
CLINICAL TRIALS REGISTRATION: NCT04647695.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
---|---|
Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 76(2023), 3 vom: 08. Feb., Seite e216-e226 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tam, Anthony Raymond [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 27.02.2023 Date Revised 27.02.2023 published: Print ClinicalTrials.gov: NCT04647695 Citation Status MEDLINE |
---|
doi: |
10.1093/cid/ciac523 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM342837923 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM342837923 | ||
003 | DE-627 | ||
005 | 20231226015034.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/cid/ciac523 |2 doi | |
028 | 5 | 2 | |a pubmed24n1142.xml |
035 | |a (DE-627)NLM342837923 | ||
035 | |a (NLM)35762834 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tam, Anthony Raymond |e verfasserin |4 aut | |
245 | 1 | 0 | |a Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir |b A Phase 2 Open-label Randomized Controlled Trial |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.02.2023 | ||
500 | |a Date Revised 27.02.2023 | ||
500 | |a published: Print | ||
500 | |a ClinicalTrials.gov: NCT04647695 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
520 | |a BACKGROUND: Early antiviral therapy was effective in the treatment of coronavirus disease 2019 (COVID-19). We assessed the efficacy and safety of combined interferon beta-1b and remdesivir treatment in hospitalized COVID-19 patients | ||
520 | |a METHODS: We conducted a multicentre, prospective open-label, randomized-controlled trial involving high-risk adults hospitalized for COVID-19. Patients were randomly assigned to a 5-day interferon beta-1b 16 million units daily and remdesivir 200 mg loading on day 1 followed by 100 mg daily on day 2 to 5 (combination group), or to remdesivir only of similar regimen (control group) (1:1). The primary endpoint was the time to complete alleviation of symptoms (NEWS2 = 0) | ||
520 | |a RESULTS: Two-hundred and twelve patients were enrolled. The median days of starting treatment from symptom onset was 3 days. The median age was 65 years, and 159 patients (75%) had chronic disease. The baseline demographics were similar. There was no mortality. For the primary endpoint, the combination group was significantly quicker to NEWS2 = 0 (4 vs 6.5 days; hazard ratio [HR], 6.59; 95% confidence interval [CI], 6.1-7.09; P < .0001) when compared to the control group. For the secondary endpoints, the combination group was quicker to negative nasopharyngeal swab (NPS) viral load (VL) (6 vs 8 days; HR, 8.16; 95% CI, 7.79-8.52; P < .0001) and to develop seropositive immunoglobulin G (IgG) (8 vs 10 days; HR, 10.78; 95% CI, 9.98-11.58; P < .0001). All adverse events resolved upon follow-up. Combination group (HR, 4.1 95% CI, 1.9-8.6, P < .0001) was the most significant independent factor associated with NEWS2 = 0 on day 4 | ||
520 | |a CONCLUSIONS: Early treatment with interferon beta-1b and remdesivir was safe and better than remdesivir only in alleviating symptoms, and in shortening viral shedding and hospitalization with earlier seropositivity in high-risk COVID-19 patients | ||
520 | |a CLINICAL TRIALS REGISTRATION: NCT04647695 | ||
650 | 4 | |a Clinical Trial, Phase II | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a early | |
650 | 4 | |a high-risk | |
650 | 4 | |a interferon beta-1b | |
650 | 4 | |a remdesivir | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Interferon beta-1b |2 NLM | |
650 | 7 | |a 145155-23-3 |2 NLM | |
650 | 7 | |a remdesivir |2 NLM | |
650 | 7 | |a 3QKI37EEHE |2 NLM | |
700 | 1 | |a Zhang, Ricky Ruiqi |e verfasserin |4 aut | |
700 | 1 | |a Lung, Kwok-Cheung |e verfasserin |4 aut | |
700 | 1 | |a Liu, Raymond |e verfasserin |4 aut | |
700 | 1 | |a Leung, Ka-Yi |e verfasserin |4 aut | |
700 | 1 | |a Liu, Danlei |e verfasserin |4 aut | |
700 | 1 | |a Fan, Yujing |e verfasserin |4 aut | |
700 | 1 | |a Lu, Lu |e verfasserin |4 aut | |
700 | 1 | |a Lam, Athene Hoi-Ying |e verfasserin |4 aut | |
700 | 1 | |a Chung, Tom Wai-Hin |e verfasserin |4 aut | |
700 | 1 | |a Yip, Cyril Chik-Yan |e verfasserin |4 aut | |
700 | 1 | |a Lo, Jenny |e verfasserin |4 aut | |
700 | 1 | |a Wu, Alan Ka-Lun |e verfasserin |4 aut | |
700 | 1 | |a Lee, Rodney |e verfasserin |4 aut | |
700 | 1 | |a Sin, Simon |e verfasserin |4 aut | |
700 | 1 | |a Ng, Pauline Yeung |e verfasserin |4 aut | |
700 | 1 | |a Chan, Wai-Ming |e verfasserin |4 aut | |
700 | 1 | |a Shum, Hoi-Ping |e verfasserin |4 aut | |
700 | 1 | |a Yan, Wing-Wa |e verfasserin |4 aut | |
700 | 1 | |a Chan, Jasper Fuk-Woo |e verfasserin |4 aut | |
700 | 1 | |a Cheng, Vincent Chi-Chung |e verfasserin |4 aut | |
700 | 1 | |a Lau, Chak-Sing |e verfasserin |4 aut | |
700 | 1 | |a To, Kelvin Kai-Wang |e verfasserin |4 aut | |
700 | 1 | |a Chan, Kwok-Hung |e verfasserin |4 aut | |
700 | 1 | |a Yuen, Kwok-Yung |e verfasserin |4 aut | |
700 | 1 | |a Hung, Ivan Fan-Ngai |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 76(2023), 3 vom: 08. Feb., Seite e216-e226 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
773 | 1 | 8 | |g volume:76 |g year:2023 |g number:3 |g day:08 |g month:02 |g pages:e216-e226 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciac523 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 76 |j 2023 |e 3 |b 08 |c 02 |h e216-e226 |